Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study

被引:17
作者
Tortelli, R. [1 ]
Copetti, M. [2 ]
Panza, F. [1 ,3 ,4 ,5 ]
Fontana, A. [2 ]
Cortese, R. [3 ]
Capozzo, R. [1 ]
Introna, A. [3 ]
D'Errico, E. [3 ]
Zoccolella, S. [3 ]
Arcuti, S. [1 ]
Seripa, D. [4 ,5 ]
Simone, I. L. [3 ]
Logroscino, G. [1 ,3 ]
机构
[1] Univ Bari Aldo Moro, Unit Neurodegenerat Dis, Dept Clin Res Neurol, Lecce, Italy
[2] IRCCS Casa Sollievo Sofferenza, Unit Biostat, Foggia, Italy
[3] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy
[4] IRCCS Casa Sollievo Sofferenza, Geriatr Unit, Dept Med Sci, Foggia, Italy
[5] IRCCS Casa Sollievo Sofferenza, Lab Gerontol & Geriatr, Dept Med Sci, Foggia, Italy
关键词
additional spreading; amyotrophic lateral sclerosis; generalization; prognosis; survival; DOUBLE-BLIND; ALSFRS-R; PLACEBO; DEXPRAMIPEXOLE; HETEROGENEITY; EPIDEMIOLOGY; DIAGNOSIS; EFFICACY; FOCALITY; SPREAD;
D O I
10.1111/ene.12994
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: A strong association between time to generalization (TTG), considered as the time of spreading of the clinical signs from spinal or bulbar localization to both, and survival was recently identified in patients with amyotrophic lateral sclerosis (ALS). Thus, TTG may be used as an early to intermediate end-point in survival studies. The aim of the present study was to test TTG as a predictor of survival in ALS. Methods: This was an observational retrospective study of ALS patients from a tertiary referral centre over a 5-year follow-up period. Results: In 212 ALS patients, TTG was associated with time to death/tracheostomy [R 0.62, 95% confidence interval (CI) 0.53-0.70; P < 0.001]. In a time-to-event analysis, longer TTG resulted in lower risk to reach a composite outcome (death or tracheostomy) both in univariate [hazard ratio (HR) 0.98, 95% CI 0.97-0.99] and multivariate Cox analyses (HR 0.98, 95% CI 0.96-0.99). TTG predicted death/tracheostomy at 4 years (C-statistic 0.58; 95% CI 0.53-0.63) and at 5 years (C-statistic 0.58; 95% CI 0.53-0.62). Conclusions: Based on the present results from a large clinical cohort, TTG may be used as a new early to intermediate end-point to describe the ALS natural history. TTG may be potentially useful as a new primary outcome measure for clinical trials.
引用
收藏
页码:1117 / 1125
页数:9
相关论文
共 40 条
  • [1] Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
    Abe, Koji
    Itoyama, Yasuto
    Sobue, Gen
    Tsuji, Shoji
    Aoki, Masashi
    Doyu, Manabu
    Hamada, Chikuma
    Kondo, Kazuoki
    Yoneoka, Takatomo
    Akimoto, Makoto
    Yoshino, Hiide
    [J]. AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2014, 15 (7-8) : 610 - 617
  • [2] EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force
    Andersen, Peter M.
    Abrahams, Sharon
    Borasio, Gian D.
    de Carvalho, Mamede
    Chio, Adriano
    Van Damme, Philip
    Hardiman, Orla
    Kollewe, Katja
    Morrison, Karen E.
    Petri, Susanne
    Pradat, Pierre-Francois
    Silani, Vincenzo
    Tomik, Barbara
    Wasner, Maria
    Weber, Markus
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (03) : 360 - E24
  • [3] [Anonymous], 2007, BMJ
  • [4] Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis
    Beghi, Ettore
    Millul, Andrea
    Logroscino, Giancarlo
    Vitelli, Eugenio
    Micheli, Anna
    [J]. AMYOTROPHIC LATERAL SCLEROSIS, 2008, 9 (03): : 163 - 167
  • [5] Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS
    Beghi, Ettore
    Pupillo, Elisabetta
    Bonito, Virginio
    Buzzi, Paolo
    Caponnetto, Claudia
    Chio, Adriano
    Corbo, Massimo
    Giannini, Fabio
    Inghilleri, Maurizio
    La Bella, Vincenzo
    Logroscino, Giancarlo
    Lorusso, Lorenzo
    Lunetta, Christian
    Mazzini, Letizia
    Messina, Paolo
    Mora, Gabriele
    Perini, Michele
    Quadrelli, Maria Lidia
    Silani, Vincenzo
    Simone, Isabella L.
    Tremolizzo, Lucio
    [J]. AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2013, 14 (5-6) : 397 - 405
  • [6] The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials
    Beghi, Ettore
    Chio, Adriano
    Couratier, Philippe
    Esteban, Jesus
    Hardiman, Orla
    Logroscino, Giancarlo
    Millul, Andrea
    Mitchell, Douglas
    Preux, Pierre-Marie
    Pupillo, Elisabetta
    Stevic, Zorica
    Swingler, Robert
    Traynor, Bryan J.
    Van den Berg, Leonard H.
    Veldink, Jan H.
    Zoccolella, Stefano
    [J]. AMYOTROPHIC LATERAL SCLEROSIS, 2011, 12 (01): : 1 - 10
  • [7] The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials
    Berry, James D.
    Miller, Robert
    Moore, Dan H.
    Cudkowicz, Merit E.
    Van den Berg, Leonard H.
    Kerr, Douglas A.
    Dong, Yingwen
    Ingersoll, Evan W.
    Archibald, Donald
    [J]. AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2013, 14 (03) : 162 - 168
  • [9] The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
    Cedarbaum, JM
    Stambler, N
    Malta, E
    Fuller, C
    Hilt, D
    Thurmond, B
    Nakanishi, A
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 169 (1-2) : 13 - 21
  • [10] Early symptom progression rate is related to ALS outcome -: A prospective population-based study
    Chiò, A
    Mora, G
    Leone, M
    Mazzini, L
    Cocito, D
    Giordana, MT
    Bottacchi, E
    Mutani, R
    [J]. NEUROLOGY, 2002, 59 (01) : 99 - 103